Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at Guggenheim Securities Inflammation & Immunology Conference Transcript

Nov 07, 2023 / 06:10PM GMT
Release Date Price: $54.72 (+0.27%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

All right. Great. So welcome to the fireside chat with Incyte this afternoon. My name is Michael Schmidt. I'm a biotech analyst with Guggenheim. It's my great pleasure to welcome Herve Hoppenot, CEO; as well as Jim Lee, who heads the [IAI] portfolio at Incyte. Welcome, and thanks for joining us.

Herve Hoppenot
Incyte Corporation - CEO & Chairman

Well, thanks for inviting us.

James H. Lee
Incyte Corporation - Group VP, Head of Inflammation & AutoImmunity Group

Thank you. Nice to be here.

Questions & Answers

Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

So maybe just starting out with a broader question. We'd like to focus on the IAI portfolio today, perhaps more so than oncology. But with Opzelura, you've sort of set the stage to the commercial product launching at the moment to expand your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot